Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases

Frontiers in Medicine

Khalaf Kridin¹  Katja Bieber²  Ralf J. Ludwig²  Enno Schmidt²  Kyle T. Amber⁴  Connor Cole⁴  Michael Hertl⁵  Dario Didona⁵  Alexander Hackel⁶  Anja Schumann⁶  Gabriela Riemekasten⁶  Hanna Graßhoff⁶  Joshua Dan⁸  Gant Sprow⁸  Victoria P. Werth⁸  Angela M. Christiano⁹  Tanya Sezin⁹  Kerstin Wolk^1,11  Robert Sabat^1,11  Sonja Ständer^1,12  Hideyuki Ujiie^1,13  David Rosmarin^1,14  Katharina Boch^1,15  Andreas Recke^1,15  Detlef Zillikens^1,15  Marcus Maurer^1,17  Martin Metz^1,17  Diamant Thaci^1,18  Michael P. Schön^2,20 

[1] 0Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel;0Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany;1Division of Dermatology, Rush University Medical Center, Chicago, IL, United States;2Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States;3Department of Dermatology and Allergology, Philipps-Universität, Marburg, Germany;4Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany;5Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States;6Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, United States;7Department of Dermatology, Columbia University Medical Center, New York, NY, United States;8Psoriasis Research and Treatment Centre, Charité—Universitätsmedizin Berlin, Berlin, Germany;9Interdisciplinary Group Molecular Immunopathology, Dermatology/Medical Immunology, Charité—Universitätsmedizin Berlin, Berlin, Germany;Center for Chronic Pruritus, Department of Dermatology, University Hospital Muenster, Muenster, Germany;Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan;Department of Dermatology, Tufts Medical Center, Boston, MA, United States;Department of Dermatology, University of Lübeck, Lübeck, Germany;Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany;Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany;Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany;Institute for Allergology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany;Lower Saxony Institute of Occupational Dermatology, University Medical Center Göttingen, Göttingen, Germany;

关键词: medical need;    skin;    inflammation;    atopic dermatitis;    psoriasis;    alopecia areata;   

DOI  :  10.3389/fmed.2022.875492

来源: DOAJ

【 摘 要 】

An estimated 20–25% of the population is affected by chronic, non-communicable inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most frequent chronic inflammatory skin diseases are atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, driven by a complex interplay of genetics and environmental factors. Autoimmunity is another important cause of chronic skin inflammation. The autoimmune response may be mainly T cell driven, such as in alopecia areata or vitiligo, or B cell driven in chronic spontaneous urticaria, pemphigus and pemphigoid diseases. Rare causes of chronic skin inflammation are autoinflammatory diseases, or rheumatic diseases, such as cutaneous lupus erythematosus or dermatomyositis. Whilst we have seen a significant improvement in diagnosis and treatment, several challenges remain. Especially for rarer causes of chronic skin inflammation, early diagnosis is often missed because of low awareness and lack of diagnostics. Systemic immunosuppression is the treatment of choice for almost all of these diseases. Adverse events due to immunosuppression, insufficient therapeutic responses and relapses remain a challenge. For atopic dermatitis and psoriasis, a broad spectrum of innovative treatments has been developed. However, treatment responses cannot be predicted so far. Hence, development of (bio)markers allowing selection of specific medications for individual patients is needed. Given the encouraging developments during the past years, we envision that many of these challenges in the diagnosis and treatment of chronic inflammatory skin diseases will be thoroughly addressed in the future.

【 授权许可】

Unknown